Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Leucovorin Calcium Injection Articles

APP buys Bigmar's European facility and products

2 August 2004

FDA knocks back B-MS cancer drug UFT

26 March 2001

B-MS launches oral chemotherapy for colorectal cancer in UK

9 March 2001

Euro colorectal cancer therapy market to 2006

16 January 2001

B-MS wins FDA OK for new Videx drug

3 November 2000

B-MS shares nosedive on Vanlev NDA withdrawal, refiling in one year

20 April 2000

Immunex' cancer drug pricing investigated

22 March 2000

Mixed fortunes for companies from latest ODAC deliberations

21 September 1999

FDA plans review of guidances on development of generic drugs

14 July 1999

B-MS set to spend $100 million on AIDS programs in Africa, R&D set to rise

11 May 1999

US pharmaceutical firms weigh in with strong sales and earnings growth

29 April 1999

B-MS files oral Orzel in colorectal cancer

12 March 1999

AHP Bid For Cyanamid Will Broaden Product Range

15 August 1994

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS